DONG-A ST CO.,LTD Logo

DONG-A ST CO.,LTD

Develops and distributes ethical drugs, medical devices, and diagnostics for global healthcare.

170900 | KO

Overview

Corporate Details

ISIN(s):
KR7170900005
LEI:
Country:
South Korea
Address:
서울 동대문구 용두동 138 ~255 천호대로 64, 서울
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Dong-A ST Co., Ltd. is a specialized pharmaceutical and medical device company that spun off from Dong-A Socio Group in 2013. The company focuses on the development, manufacturing, and global distribution of ethical drugs (ETC), medical devices, and diagnostics. Its pharmaceutical portfolio includes domestically developed new drugs such as Stillen and Zydena, biopharmaceuticals, and chemical drugs. Dong-A ST is also a major global manufacturer of the tuberculosis API, Cycloserine. The medical device and diagnostics division provides comprehensive healthcare solutions in areas including ENT (Ear, Nose, Throat) equipment, in-vitro diagnostics, and infection control systems. With a strong emphasis on research and development, the company actively pursues international expansion through global partnerships and exports.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-09 00:00
Prospectus
투자설명서
Korean 2.8 MB
2025-09-09 00:00
Share Issue/Capital Change
증권발행실적보고서
Korean 47.8 KB
2025-09-08 00:00
Registration Form
[발행조건확정]증권신고서(채무증권)
Korean 14.6 KB
2025-09-03 00:00
Registration Form
[기재정정]증권신고서(채무증권)
Korean 3.1 MB
2025-09-03 00:00
Prospectus
[발행조건확정]증권신고서(채무증권)
Korean 275.8 KB
2025-08-28 00:00
Registration Form
증권신고서(채무증권)
Korean 2.8 MB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 3.3 MB
2025-08-13 00:00
Earnings Release
[기재정정]영업(잠정)실적(공정공시)
Korean 18.0 KB
2025-07-25 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 239.2 KB
2025-07-24 00:00
Earnings Release
영업(잠정)실적(공정공시)
Korean 13.8 KB
2025-07-24 00:00
Report Publication Announcement
기업설명회(IR)개최(안내공시)
Korean 6.6 KB
2025-07-18 00:00
Report Publication Announcement
결산실적공시예고(안내공시)
Korean 4.1 KB
2025-07-18 00:00
Report Publication Announcement
기업설명회(IR)개최(안내공시)
Korean 6.8 KB
2025-07-07 00:00
Major Shareholding Notification
최대주주등소유주식변동신고서
Korean 61.5 KB
2025-07-07 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.7 KB

Automate Your Workflow. Get a real-time feed of all DONG-A ST CO.,LTD filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for DONG-A ST CO.,LTD

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for DONG-A ST CO.,LTD via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Monte Rosa Therapeutics, Inc. Logo
Develops molecular glue degraders to target undruggable proteins in cancer and immune diseases.
United States of America
GLUE
Develops LNP drug delivery systems for severe diseases, offering R&D to GMP manufacturing support.
South Korea
322970
MORISHITA JINTAN CO.,LTD. Logo
Manufactures health products and provides OEM/ODM services using advanced encapsulation technology.
Japan
4524
MUROMACHI CHEMICALS INC. Logo
A diversified manufacturer of pharmaceuticals, chemical systems, health foods & functional materials.
Japan
4885
MUSTANG BIO, INC. Logo
Developing CAR T-cell and gene therapies for cancers and rare genetic disorders.
United States of America
MBIO
MYUNGMOON PHARM CO.,LTD Logo
Develops, manufactures, and commercializes prescription & OTC medicines for global markets.
South Korea
017180
Nanexa AB Logo
Develops long-acting injectables using its proprietary nanotechnology for its own pipeline and partners.
Sweden
NANEXA
Nanobiotix Logo
Develops a first-in-class radioenhancer to amplify radiotherapy's effect directly within tumors.
France
NANO
Nanobiotix S.A. Logo
Developing a nanotherapeutic radioenhancer that amplifies radiation to destroy solid tumors.
United States of America
NBTX
Nanoform Finland OYJ Logo
Pharma tech firm engineering nanoparticles to enhance drug performance and development.
Finland
NANOFH

Talk to a Data Expert

Have a question? We'll get back to you promptly.